What are the side effects of Tapazole (methimazole)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Tapazole (Methimazole)

Methimazole (Tapazole) can cause potentially life-threatening adverse reactions including agranulocytosis, hepatotoxicity, and vasculitis, requiring immediate medical attention if symptoms develop. 1

Common Side Effects

  • Gastrointestinal disturbances including nausea and vomiting 2
  • Skin reactions such as pruritus and rash 2
  • Dose-dependent hypothyroidism requiring routine monitoring of thyroid function 1
  • Arthralgias (joint pain) in 1-5% of patients 2

Serious Adverse Effects

Hematologic Toxicity

  • Agranulocytosis - potentially life-threatening reaction typically occurring within the first three months of treatment with an incidence of 3 per 10,000 patients 2
    • Symptoms include fever, sore throat, and general malaise 1
    • Risk increases in a dose-dependent manner (0.13% at 10 mg/day to 0.47% at 30 mg/day) 3
  • Leukopenia and thrombocytopenia may occur 1
  • Isolated thrombocytopenia can develop even after long-term use of low-dose methimazole 4
  • Aplastic anemia (pancytopenia) - rare but serious 1, 2

Hepatotoxicity

  • Liver dysfunction with symptoms including anorexia, pruritus, and right upper quadrant pain 1
  • Elevated liver enzymes (ALT, AST) exceeding 3 times the upper limit of normal require immediate discontinuation 1
  • Risk of hepatotoxicity appears to be lower with methimazole than with propylthiouracil, especially in pediatric populations 1

Vasculitis

  • Can result in severe complications including:
    • Leukocytoclastic cutaneous vasculitis
    • Acute kidney injury and glomerulonephritis
    • Alveolar/pulmonary hemorrhage
    • CNS vasculitis and neuropathy 1
  • Often associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis 1
  • May require treatment with corticosteroids, immunosuppressants, and plasmapheresis in severe cases 1

Teratogenic Effects

  • First trimester use associated with congenital malformations including:
    • Aplasia cutis
    • Craniofacial malformations (facial dysmorphism, choanal atresia)
    • Gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula)
    • Omphalocele and abnormalities of the omphalomesenteric duct 1
  • Propylthiouracil is generally preferred during the first trimester of pregnancy due to lower teratogenic risk 2, 5

Monitoring and Management

Monitoring Recommendations

  • Regular assessment of thyroid function (TSH and free T4) to prevent hypothyroidism 1
  • Complete blood count monitoring, especially during the first three months of treatment 3
  • Liver function tests if symptoms of hepatic dysfunction develop 1

Management of Side Effects

  • For minor skin reactions (rash, pruritus), switching from methimazole to propylthiouracil may be considered, though cross-reactions can occur 2
  • For patients with non-serious side effects to methimazole (excluding agranulocytosis and hepatotoxicity), desensitization under allergist supervision is a potential option 6
  • For agranulocytosis, immediate discontinuation of the drug is required 1
    • Granulocyte colony-stimulating factor (G-CSF) can hasten recovery and reduce morbidity 7
  • For vasculitis, discontinue therapy and initiate appropriate intervention 1

Important Precautions

  • Patients should be instructed to immediately report symptoms of agranulocytosis (fever, sore throat), hepatotoxicity (anorexia, right upper quadrant pain), or vasculitis 1
  • Arthralgias may be the first symptom of more serious immunologic side effects and may warrant drug discontinuation 2
  • Cross-reactivity between methimazole and carbimazole should be expected as carbimazole is rapidly metabolized to methimazole 2

References

Research

[Pharmacotherapy of hyperthyreosis--adverse drug reactions].

Therapeutische Umschau. Revue therapeutique, 2011

Guideline

Abrupt Switching from Propylthiouracil (PTU) to Methimazole

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Desensitization to Methimazole.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2021

Research

Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).

Thyroid : official journal of the American Thyroid Association, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.